Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 50 of 54 publications.

Khan S, Copley-Merriman K, Heyes A, Hawe E, Hartley L, Kallmes K. Qualitative and quantitative evidence synthesis strategies to support JCA and IRA submissions. Poster to be given at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain.

Gildea L, Arvin-Berod C, Heyes A, Heyerick A, Urdaniz E, Vainilovich Y, Trainor L, Densmore D. Evidence gap analysis of the burden of illness and treatment of thyroid eye disease. Poster presented at the ISPOR 2024; May 7, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S35. doi: 10.1016/j.jval.2024.03.184

Lyall M, Crawford R, Bell T, Mamolo C, Neuhof A, Levy C, Heyes A. Characterizing the patient journey in multiple myeloma: qualitative review. JMIR Cancer. 2022 Sep 22;8(3):E39068. doi: 10.2196/39068

Sarda SP, Heyes A, Bektas M, Thankur T, Chao W, Intorcia M, Wronski S, Jones DL. Humanistic and economic burden of geographic atrophy: a systematic literature review. Clin Opththa. 2021 Dec 8;2021(15):4629-44.

D'Souza V, Njue A, Heyes A. DRG-based reimbursement and payment modalities for innovative remote patient monitoring technologies. Poster presented at the Virtual ISPOR Europe 2021; December 1, 2021. [abstract] Value Health. 2021 Dec; 24(12):S2.

Jones DL, Bektas M, Heyes A, Wronski S, Sarda SP. Clinical & humanistic burden of geographic atrophy (GA). Poster presented at the 2021 EURETINA Virtual Congress; September 9, 2021.

Han E, Lu E, Heyes A, Mauskopf J, Bracher M, Birch H. Common symptoms in hospitalized COVID-19 patients by age, severity and survival outcome – A literature review. Poster presented at the ERS International Congress 2021; September 5, 2021.

Han E, Lu E, Heyes A, Mauskopf J, Birch H, Bracher M. The use of pharmacological therapies in hospitalized COVID-19 patients – a literature review. Poster presented at the ERS International Congress 2021; September 5, 2021.

Lu E, Han E, Heyes AE, Mauskopf J, Bracher MG, Birch HJ. Economic burden associated with clinical management of COVID-19 – a literature review. Poster presented at the ERS International Congress 2021; September 5, 2021.

Levy C, Bell T, Lyall M, Mamolo C, Neuhof A, Crawford R, Heyes A. The patient experience of multiple myeloma: symptoms and health-related quality of life. Poster presented at the EHA2021 Virtual Congress; June 9, 2021. [abstract] Hemasphere. 2021; 5(S2):789.

Crawford R, Bell T, Levy C, Mamolo C, Lyall M, Neuhof A, Heyes A. The impact of COVID-19 on patient disease experience: insights from social media posts contributed by patients with multiple myeloma. Poster presented at the EHA2021 Virtual Congress; June 9, 2021. [abstract] Hemasphere. 2021; 5(S2).

Lyall M, Heyes A, Bell T, Mamolo C, Neuhof A, Levy C, Crawford R. Multiple myeloma treatment decisions from the patient perspective. Poster presented at the EHA2021 Virtual Congress; June 9, 2021. [abstract] Hemasphere. 2021; 5(S2):788.

Heyes AE, Nuabor WA, Costello JJ, Mauskopf JM, Petitiean A, Andrew MK. Posthospitalisation outcomes in older patients hospitalised for influenza: a comprehensive literature review. Poster presented at the 2020 Virtual 7th ESWI Influenza Conference; December 6, 2020.

Heyes A, Millar (Gildea) L. Early dialogue with NICE and EUnetHTA: a UK perspective in a politically uncertain era. Poster presented at the ISPOR 2019 European Conference; November 4, 2019. Copenhagen, Denmark. [abstract] Value Health. 2019 Dec; 22(S3).

Costello J, Njue A, Lyall M, Heyes A, Mahler N, Philbin M, Nazareth T. Efficacy, safety, and quality-of-life of treatments for acute relapses of multiple sclerosis: results from a literature review of randomized controlled trials. Degener Neurol Neuromuscul Dis. 2019 Jul 1;9:55-78. doi: 10.2147/DNND.S208815

Domdey A, Njue A, Nuabor W, Lyall M, Heyes A, Elliott L. Allergy immunotherapies for allergic rhinitis: systematic review and assessment of evolving quality. Eur Ann Allergy Clin Immunol. 2019 Jul;51(4):147-58. doi: 10.23822/EurAnnACI.1764-1489.100

Heyes A, McBride D, Pearson I, Copley-Merriman C. HTA and reimbursement considerations for rare diseases in European markets: what are the implications for manufacturers? Poster presented at the 2018 ISPOR 21st Annual European Congress; November 12, 2018. Barcelona, Spain.

Winfree KB, Ainsworth C, Njue A, Molife C, Lyall M, Jen M-H, Bittoni M, Heyes A, Carbone DP. Defining aggressive disease in patients with advanced NSCLC receiving second-line treatment: a systematic review. Poster presented at the IASLC 19th World Conference on Lung Cancer; September 26, 2018. Toronto, Canada. [abstract] J Thorac Oncol. 2018 Oct; 13(10 (Suppl)):5908. doi: 10.1016/j.jtho.2018.08.1671

Drahos J, Evans E, Stevenson A, Heyes A, Hoffman D. A comprehensive burden-of-illness review for Type 1 and Type 2 narcolepsy. Poster presented at the 7th International Narcolepsy Symposium 2018; September 9, 2018. Beverly, MA.

Doyle S, Njue A, Lyall M, Rushton R, Heyes A, Kelly M. Systematic review of the clinical effectiveness of treatments in eosinophilic granulomatosis with polyangiitis. Poster presented at the 2018 ACR/ARHP Annual Meeting; October 22, 2018. Chicago, IL. [abstract] Arthritis Rheumatol. 2018 Sep; 70(S9):1944. doi: 10.1002/art.40700

Winfree KB, Ainsworth C, Njue A, Molife C, Lyall M, Jen MH, Bittoni M, Heyes A, Carbone DP. Novel antiangiogenic drugs, immune checkpoint inhibitors, and chemotherapy in patients with aNSCLC who have aggressive disease: a systematic review. J Clin Oncol. 2018 May 16;36(15_suppl):e21120-e. doi: 10.1200/JCO.2018.36.15_suppl.e21120

Njue A, Domdey A, Zimovetz E, Lyall M, Heyes AE, Valovirta E. The burden of comorbid allergic rhinitis and asthma. Poster presented at the 2016 ISPOR 19th Annual European Congress; November 1, 2016. Vienna, Austria. [abstract] Value Health. 2016 Nov; 19(7):A548.

Hogue SL, Bjoerk B, Walker A, Balp M, Fernandez MM, Quijano M, Ling CS, Heyes AE. Evidence-based market access value resource: navigating the hurdles for a biologic obtaining a license in a second indication in key European countries. Poster presented at the 2014 ISPOR 17th Annual European Congress; November 2014. Amsterdam. [abstract] Value Health. 2014 Nov; 17(7):A431-2.

Ling CS, Heyes AE. Pricing and reimbursement environment for a biologic obtaining a licence in a second indication in key European countries. Poster presented at the 2014 ISPOR 17th Annual European Congress; November 2014. Amsterdam, The Netherlands.

Ainsworth C, Kiri S, Ling CS, Heyes AE, Hass B. The global burden, incidence, and prevalence of chronic hepatitis c. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. Dublin, Ireland. [abstract] Value Health. 2013 Nov; 16(7):A342.

Hogue S, Hollis K, McLeod L, Brogan AP, Heyes A. European payer advisors' use of observational studies for health care reimbursement decisions. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013.

Ling CS, Weisgerber-Kriegl U, Njue AI, Heyes A, Kaye J. The effect of positive margins on outcomes in breast cancer. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. [abstract] Value Health. 2013 Nov; 16(7):A394.

Heyes A, Lebiecki J, Serup-Hansen N, Andreasen J. Identification of cost-drivers in the management of patients with allergic rhinitis. Poster presented at the XXXI Congress of the European Academy of Allergy and Clinical Immunology; June 2012. Geneva, Switzerland. [abstract] Allergy. 2012 Nov; 67(S96):344.

Rycroft CE, Heyes A, Lanza L, Becker K. Epidemiology of chronic obstructive pulmonary disease: a literature review. Int J Chron Obstruct Pulmon Dis. 2012 Jul 1;7:457-94.

Sherrill B, Akhras K, Kaye J, Sandin R, Cappelleri J, Heyes A, Chen C. Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology. Poster presented at the European Multidisciplinary Cancer Congress of the European Cancer Organization; September 24, 2011. Stockholm, Sweden. [abstract] Eur J Cancer. 2011 Sep 1; 47(Suppl. 1):S261.

Rycroft CE, Pearson IV, Khan S, Heyes AE. A tale of four countries: comparing reimbursement submission requirements in Ireland, England, Wales, and Scotland. Poster presented at the 2010 ISPOR 13th Annual European Congress; November 15, 2010. [abstract] Value Health. 2010 Nov; 13(7):A418-9.

Rofail D, Kitchen H, Heyes A, Heron L, Sacco P. Cognitive impairment associated with schizophrenia: the humanistic and economic burden. Poster presented at the American Neurological Association; 2010. San Francisco, CA.

Cella D, Herbst RS, Lynch TJ, Prager D, Belani CP, Schiller JH, Heyes A, Ochs JS, Wolf MK, Kay AC, Kris MG, Natale RB. Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial. J Clin Oncol. 2005 May 1;23(13):2946-54.

Yost KJ, Yount SE, Eton DT, Silberman C, Broughton-Heyes A, Cella D. Validation of the Functional assessment of cancer therapy-Breast Symptom Index (FBSI). Breast Cancer Res Treat. 2005 Apr 1;90(3):295-8.

Heyes A. Clinical trial experience with Functional Assessment of Cancer Therapy—Lung in conventional and targeted non—small cell lung cancer therapy. Semin Oncol. 2004 Jun 1;31(Suppl. 9):16-22.

Douillard JY, Cella D, Natale R, Lynch TL, Lee C, Carbone D, Kay A, Wolf M M, Heyes AE, Ward J. Clinically meaningful improvement in disease-related symptoms by 'gefitinib' (Iressa, ZD1839) in patients with advanced non-small cell lung cancer: relationship between lung cancer subscale scores and radiographic response and survival. Presented at the European Cancer Conference 12; September 2003; September 2003. Copenhagen, Denmark.

LoRusso PM, Herbst RS, Rischin D, Ranson M, Calvert H, Raymond E, Kieback D, Kaye S, Gianni L, Harris A, Bjork T, Maddox A, Rothenberg ML, Small EJ, Rubin EH, Feyereislova A, Heyes A, Averbuch SD, Ochs J, Baselga J. Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors. Clin Cancer Res. 2003 Jun 1;9(6):2040-8.

Cella D, Natale R, Lynch T T, Lee C, Carbone D, Douillard JY, Kay A, Wolf M, Heyes AE, Ward J. Disease-related symptoms in advanced nsclc as measured by the lung cancer subscale (LCS) of the fact-l questionnaire: clinically meaningful improvement with gefitinib (Iressa, ZD1839). Presented at the American Society of Clinical Oncology; May 2003. Chicago, IL.

Trump DL, Wilding G, Miller K, Small E, Soulie P, Trachtenberg J, Raabe N, Heyes AE, Das-Gupta A. Pilot trials of ZD1839 ('Iressa'), an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor, in combination with mitoxantrone/prednisolone or docetaxel/estramustine in patients with hormone-refractory prostate cancer. Presented at the American Urology Association; April 2003. Chicago, IL.

Soni MK, Cella D, Masters GA, Burch SP, Heyes AE, Silberman C. The validity and clinical utility of symptom monitoring in advanced lung cancer: a literature review. Clin Lung Cancer. 2002 Nov;4(3):153-60.

Douillard JY, Skarin A, Baselga J, Natale R, Giaccone G, Maddox A, Heyes AE. Improvement in disease-related symptoms and quality of life (QOL) in patients treated with advanced non-small cell lung cancer (NSCLC) treated with zd1839 in ideal1 and ideal2. Poster presented at the European Society for Medical Oncology; October 2002. Nice, France.

Lewis B, Silberman C, Heyes AE. Side effects of chemotherapy among patients with ovarian cancer. Presented at the International Society for Pharmacoeconomics and Outcomes Research 7th Annual International Meeting; May 2002. Washington, DC.

Dennison CR, Leidy NK, Silberman C, Heyes AE. Interpretation of quality of life data from a clinician's point of view: getting to the clinically meaningful change. Presented at the Mayo Clinic Meeting: Assessing Clinical Significance for Quality of Live Measures in Oncology Research; April 2002. Rochester, MN.

Leidy NK, Jonas D, Silberman C, Margolis MK, Heyes AE. What does it all mean? Using health-related quality of life data to interpret treatment outcomes. Presented at the Mayo Clinic Meeting: Assessing Clinical Significance for Quality of Live Measures in Oncology Research; April 2002. Rochester, MN.

Cella D, Eton DT, Faircloth DL, Bonomi P, Heyes AE, Silberman C, Wolf MK, Johnson DH. What is a clinically meaningful change on the Functional Assessment of Cancer Therapy - Lung (FACT-L) questionnaire? Results from Eastern Cooperative Group (ECOG) Study 5592. J Clin Epidemiol. 2002 Mar;55(3):285-95.

Leidy NK, Jonas D, Silberman C, Heyes AE. What role do symptoms play in health-related quality of life? Poster presented at the 8th Annual Conference of the International Society for Quality of Life Research; November 2001. Amsterdam, The Netherlands.

Jonas D, Leidy NK, Silberman C, Margolis MK, Heyes AE. Cognitive factors in symptom assessment: are we asking too much? Poster presented at the 8th Annual Conference of the International Society for Quality of Life Research; November 2001. Amsterdam, The Netherlands.

Sorensen SV, Chambers M, Heyes AE. An economic model for the pharmacological management of advanced non-small cell lung cancer in the US. Poster presented at the International Society for Pharmacoeconomics and Outcomes Research; 2001. Cannes, France. [abstract] Value Health. 2001 Sep; 4(6):403.

Anderson H, Espinosa E, Lofts F, Meehan M, Hutchinson G, Price N, Heyes AE. Evaluation of the Chemotherapy Patient Monitor: an interactive tool for facilitating communication between patients and oncologists during the cancer consultation. Eur J Cancer Care (Engl). 2001 Jun;10(2):115-23.

Cella D, Eton DT, Fairclough DL, Heyes AE, Silberman C, Wolf MK. What is a clinically meaningful change (CMC) on the functional assessment of cancer therapy - lung (FACT-L): analysis of ecog 5592 data. Poster presented at the 37th Annual Meeting of the American Society of Clinical Oncology; May 2001. San Francisco, CA.